Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis
作者： Huan Wang , Jing Huang , Xiaojin Yu , Shuhua Han , Xing Yan
DOI: 10.1007/S00432-014-1709-0
关键词: Oncology 、 Epidermal growth factor receptor 、 Hematology 、 Meta-analysis 、 Internal medicine 、 Mutation (genetic algorithm) 、 Exon 、 Analysis of variance 、 Relative risk 、 Lung cancer 、 Bioinformatics 、 Medicine
摘要: Nearly 85 % of lung-cancer-specific epidermal growth factor receptor (EGFR) sensitive mutations comprise a substitution at position 858 (21L858R) and deletion mutants in exon 19 (19del). The aim this study was to assess the role EGFR mutation subtypes predicting efficacy tyrosine kinase inhibitors (EGFR TKIs) prognosis patients with advanced non-small cell lung cancer (NSCLC). We systematically searched for eligible articles investigating association between TKIs NSCLC. summary risk ratio (RR) mean difference (MD) were calculated using meta-analysis. In addition, we used variance analysis progression-free survival data (PFS) rank sum test overall data. We identified 22 trials involving 1,082 patients. objective response rate 19del group significantly higher than 21L858R (RR 1.23; 95 % CI 1.12–1.36; P < 0.0001). PFS (MD 3.55; 0.90–6.20; P = 0.009; MD 2.57; 0.51–4.62; P = 0.01) (OS) 10.52; 5.10–15.93; P = 0.0001) longer group; same results observed test. may be more efficient clinical marker NSCLC TKIs. Furthermore, have both OS. is also prognostic
springer.com
core.ac.uk
paperity.org参考文章(33)
Stela Pudar Hozo, Benjamin Djulbegovic, Iztok Hozo, Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology. ,vol. 5, pp. 13- 13 ,(2005) , 10.1186/1471-2288-5-13
Yan Xu, Hongyu Liu, Jun Chen, Qinghua Zhou, Comparisons between the National Comprehensive Cancer Network (NCCN) non‐small‐cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009 Thoracic Cancer. ,vol. 1, pp. 83- 86 ,(2010) , 10.1111/J.1759-7714.2010.00016.X
Ming-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, Chang-Qi Zhu, Suzanne Kamel-Reid, Jeremy Squire, Ian Lorimer, Tong Zhang, Ni Liu, Manijeh Daneshmand, Paula Marrano, Gilda da Cunha Santos, Alain Lagarde, Frank Richardson, Lesley Seymour, Marlo Whitehead, Keyue Ding, Joseph Pater, Frances A. Shepherd, Erlotinib in lung cancer - molecular and clinical predictors of outcome. The New England Journal of Medicine. ,vol. 353, pp. 133- 144 ,(2005) , 10.1056/NEJMOA050736
Luis Paz-Ares, Denis Soulières, Ivan Melezínek, Joachim Moecks, Lorenz Keil, Tony Mok, Rafael Rosell, Barbara Klughammer, Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis Journal of Cellular and Molecular Medicine. ,vol. 14, pp. 51- 69 ,(2010) , 10.1111/J.1582-4934.2009.00991.X
A G Pallis, A Voutsina, Ar Kalikaki, J Souglakos, E Briasoulis, S Murray, A Koutsopoulos, M Tripaki, E Stathopoulos, D Mavroudis, V Georgoulias, ‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer British Journal of Cancer. ,vol. 97, pp. 1560- 1566 ,(2007) , 10.1038/SJ.BJC.6604068
Meina Wu, Jun Zhao, Sonya Wei Song, Minglei Zhuo, Xin Wang, Hua Bai, Shuhang Wang, Lu Yang, Tongtong An, Yan Zhang, Jianchun Duan, Yuyan Wang, Qingzhi Guo, Xuyi Liu, Ninghong Liu, Jie Wang, EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer Lung Cancer. ,vol. 67, pp. 343- 347 ,(2010) , 10.1016/J.LUNGCAN.2009.04.011
Guanghui Gao, Shengxiang Ren, Aiwu Li, Jianfang Xu, Qinghua Xu, Chunxia Su, Jian Guo, Qinfang Deng, Caicun Zhou, Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials. International Journal of Cancer. ,vol. 131, ,(2012) , 10.1002/IJC.27396
Alejandro R. Jadad, R.Andrew Moore, Dawn Carroll, Crispin Jenkinson, D.John M. Reynolds, David J. Gavaghan, Henry J. McQuay, Assessing the quality of reports of randomized clinical trials : is blinding necessary? Controlled Clinical Trials. ,vol. 17, pp. 1- 12 ,(1996) , 10.1016/0197-2456(95)00134-4
H Asahina, , K Yamazaki, I Kinoshita, N Sukoh, M Harada, H Yokouchi, T Ishida, S Ogura, T Kojima, Y Okamoto, Y Fujita, H Dosaka–Akita, H Isobe, M Nishimura, A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. British Journal of Cancer. ,vol. 95, pp. 998- 1004 ,(2006) , 10.1038/SJ.BJC.6603393
K Tamura, I Okamoto, T Kashii, S Negoro, T Hirashima, S Kudoh, Y Ichinose, N Ebi, K Shibata, T Nishimura, N Katakami, T Sawa, E Shimizu, J Fukuoka, T Satoh, M Fukuoka, Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403) British Journal of Cancer. ,vol. 98, pp. 907- 914 ,(2008) , 10.1038/SJ.BJC.6604249